source
- Ivonescimab cuts death risk by one-third in Chinese lung cancer trial, adds four-month survivalA trial in China evaluated ivonescimab combined with chemotherapy in patients newly diagnosed with advanced non-small cell lung cancer. The study was presented at the American Society of Clinical O…
- Revolution Medicines begins shipping experimental pancreatic cancer drug daraxonrasib under FDA early access programRevolution Medicines announced that it has started sending its experimental pancreatic cancer therapy, daraxonrasib, to doctors and patients through an FDA‑authorized early access program. The comp…